Ipidacrin-BP inj.

Ipidacrinum

1 ml (1 ampoule) of solution for injection contains ipidacrine hydrochloride 15 mg (available strengths: 5 mg/ml or 15 mg/ml).

1 ml (1 ampoule) of solution for injection contains ipidacrine hydrochloride 5 mg (available strengths: 5 mg/ml or 15 mg/ml).

Indication: Ipidacrine-BP is indicated for peripheral nervous system disorders (neuritis, polyneuritis, polyneuropathy, polyradiculoneuropathy, myasthenia and myasthenic syndrome), bulbar paralysis and paresis, the recovery period after organic CNS lesions with motor disturbances, combined therapy of demyelinating diseases, memory disorders of various origin (Alzheimer's disease and other forms of senile dementia), and intestinal atony.

Contraindications (SmPC sec. 4.3): 4.3 Contraindications - Hypersensitivity to ipidacrine and/or to the excipients of the preparation listed in section 6.1. - Epilepsy. - Extrapyramidal disorders with hyperkinesia. - Angina pectoris. - Marked bradycardia. - Bronchial asthma. - Intestinal obstruction or obstruction of the urinary tract. - Gastric or duodenal ulcer in the acute phase. - Vestibular disorders. - Pregnancy. - Breast-feeding.

Special warnings and precautions (SmPC sec. 4.4, excerpt): 4.4 Special warnings and precautions The medicinal product is indicated with caution in patients with gastric and duodenal ulcer, thyrotoxicosis, cardiovascular disorders, as well as in patients with a history of respiratory tract disorders and with acute respiratory tract conditions.